MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.2350
+0.0100
+4.44%
After Hours: 0.2400 +0.005 +2.13% 19:14 02/06 EST
OPEN
0.2250
PREV CLOSE
0.2250
HIGH
0.2479
LOW
0.2210
VOLUME
167.11K
TURNOVER
--
52 WEEK HIGH
1.730
52 WEEK LOW
0.2178
MARKET CAP
10.76M
P/E (TTM)
-0.4010
1D
5D
1M
3M
1Y
5Y
1D
Akari Therapeutics to Present Next-Generation ADC Platform at Webull Financial Virtual Conference
Reuters · 2d ago
Akari Therapeutics präsentiert sich auf der virtuellen Corporate Connect Webinar Series von Webull Financial
Reuters · 2d ago
Weekly Report: what happened at AKTX last week (0126-0130)?
Weekly Report · 5d ago
Akari Therapeutics files patent covering AKTX-102
TipRanks · 01/26 13:51
Akari Therapeutics Files U.S. Provisional Patent Application Covering Second Pipeline Candidate, AKTX-102, ADC Directed Against CEACAM5
Benzinga · 01/26 13:46
Akari Therapeutics Files Patent Application for New ADC Candidate AKTX-102 Targeting CEACAM5 in Solid Tumors
Reuters · 01/26 13:45
AKARI THERAPEUTICS FILES KEY PATENT AND UNVEILS SECOND ADC PROGRAM AKTX-102 TARGETING CEACAM5 EXPRESSING SOLID TUMORS
Reuters · 01/26 13:45
Weekly Report: what happened at AKTX last week (0119-0123)?
Weekly Report · 01/26 10:32
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.